You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1536 Results
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Sep 2025
Drug
Other Name(s): Camptosar®
Updated
Sep 2025
Drug
Other Name(s): Imbruvica®
Updated
Sep 2025
The Canada Post service disruption may affect the delivery of cancer screening letters and fecal immunochemical test (FIT) kits for colorectal...
Drug
Other Name(s): Tibsovo®
Updated
Oct 2025
Our Comprehensive Cancer Biomarker Testing Program supports patient management through the testing of diagnostic, predictive and prognostic markers....
Drug
Other Name(s): Truqap™
Updated
Oct 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    capivasertib - For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, based on criteria
ODB - General Benefit
    fulvestrant
Updated
Oct 2025

Pages